Resumen de acción ICPT
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Recompensas
Análisis de riesgos
Competidores de Intercept Pharmaceuticals, Inc.
Historial de precios y rendimiento
| Historical stock prices | |
|---|---|
| Current Share Price | US$19.00 |
| 52 Week High | US$21.86 |
| 52 Week Low | US$8.82 |
| Beta | 0.88 |
| 1 Month Change | 1.99% |
| 3 Month Change | 81.30% |
| 1 Year Change | 19.12% |
| 3 Year Change | -50.68% |
| 5 Year Change | -81.17% |
| Change since IPO | -2.06% |
Noticias y actualizaciones recientes
Recent updates
Revenues Working Against Intercept Pharmaceuticals, Inc.'s (NASDAQ:ICPT) Share Price Following 25% Dive
Jun 08
Intercept Pharmaceuticals (NASDAQ:ICPT) Has Debt But No Earnings; Should You Worry?
Apr 11Health Check: How Prudently Does Intercept Pharmaceuticals (NASDAQ:ICPT) Use Debt?
Dec 20Intercept touts Ocaliva benefit in transplant-free survival in liver disease type
Sep 20Intercept cuts debt further with deal to exchange convertible notes
Sep 02Intercept reduces debt with repurchases of $327.9M convertible notes
Aug 19Intercept Pharmaceuticals: Too Risky To Buy At This Stage
Aug 13Intercept Pharma Q2 2022 Earnings Preview
Aug 02Intercept to resubmit for FDA approval of NASH candidate after new analysis
Jul 07Intercept: Increase Of Ocaliva Sales And A Few Catalysts
May 23Need To Know: Analysts Are Much More Bullish On Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT)
May 10Intercept: Opportunity To Buy On Potential NDA Resubmission Of Ocaliva For NASH
Mar 05Intercept names Andrew Saik as chief financial officer
Jun 07Intercept Pharmaceuticals slides as FDA restricts Ocaliva use
May 26Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT): Are Analysts Optimistic?
May 11Rentabilidad de los accionistas
| ICPT | US Biotechs | Mercado US | |
|---|---|---|---|
| 7D | 0.1% | 4.7% | 0.7% |
| 1Y | 19.1% | 2.7% | 23.9% |
Rentabilidad vs. Industria: ICPT superó al sector US Biotechs , que obtuvo un rendimiento del -3.7% el año pasado.
Rentabilidad vs. Mercado: ICPT superó al mercado US, que obtuvo un rendimiento del 19.3% el año pasado.
Volatilidad de los precios
| ICPT volatility | |
|---|---|
| ICPT Average Weekly Movement | 22.8% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.0% |
Precio estable de las acciones: El precio de las acciones de ICPT ha sido volátil en los últimos 3 meses.
Volatilidad a lo largo del tiempo: La volatilidad semanal de ICPT ha aumentado de 15% a 23% en el último año.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 2002 | 341 | Jerry Durso | www.interceptpharma.com |
Resumen de fundamentos de Intercept Pharmaceuticals, Inc.
| Estadísticas fundamentales de ICPT | |
|---|---|
| Capitalización bursátil | US$794.69m |
| Beneficios(TTM) | -US$57.47m |
| Ingresos (TTM) | US$317.68m |
2.5x
Ratio precio-ventas (PS)-13.8x
Ratio precio-beneficio (PE)¿Está ICPT sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de ICPT | |
|---|---|
| Ingresos | US$317.68m |
| Coste de los ingresos | US$632.00k |
| Beneficio bruto | US$317.05m |
| Otros gastos | US$374.52m |
| Beneficios | -US$57.47m |
Últimos beneficios comunicados
Sep 30, 2023
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | -1.37 |
| Margen bruto | 99.80% |
| Margen de beneficio neto | -18.09% |
| Ratio deuda/patrimonio | 311.6% |
¿Cómo se ha desempeñado ICPT a largo plazo?
Ver rendimiento histórico y comparativa